FDA recalls Hemopropin Ointment due to manufacturing process deviations
Apipharma is voluntarily recalling Hemopropin Ointment due to manufacturing process deviations. Approximately 4,218 boxes distributed in Arizona are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary recall initiated by the firm due to Current Good Manufacturing Practice deviations. The rubric specifically categorizes voluntary precautionary recalls as Moderate severity when no illnesses or injuries are reported in the source.
Plain-English summary
Hemopropin Ointment is being recalled due to manufacturing process deviations. The topical ointment contains Lanolin 17.76% and Petrolatum 71.2% and was manufactured in Croatia. The recall affects approximately 4,218 boxes distributed in Arizona.
The company, Apipharma LLC, voluntarily initiated the recall on April 9, 2025. The affected products are identified by lot numbers A00001 (expiration December 2027), A00005 (expiration January 2027), and B00001 (expiration February 2028), with UPC codes 3 858882 103534 and 3 858882 101318.
Consumers who have this product should discontinue use and contact Apipharma or their healthcare provider with questions about the recall.
The recalled product
- Product
- Hemopropin Ointment, Lanolin 17.76% and Petrolatum 71.2%, Net Wt. 0.7 oz (20g) tubes, Manufactured by: Apipharma d.o.o, Croatia, Distributed by: Apipharma, LLC, Tempe, AZ UPC 3 858882 103534 and UPC 3 858882 101318
- Manufacturer
- Apipharma
- Category
- Drug — Topical Ointment
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: A00001
- Exp.: 2027-12
- A00005
- Exp.: 2027-01
- B00001
- Exp.:2028-02
Distribution
Distributed in 1 state:
- AZ
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27